GERON
Geron designs, manufactures, and sells textile carding equipments.
GERON
Social Links:
Industry:
Machinery Manufacturing Manufacturing Textiles
Founded:
1987-01-01
Status:
Active
Contact:
86513-8517 8888
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Font Awesome Apache Mobile Non Scaleable Content Nginx PHP Apache 2.4
Similar Organizations
Norwalk Compressor
Norwalk Compressor designs, manufactures and services compression equipment.
Toread Holdings Group
Toread Holdings Group designs, manufactures, and retails camping and outdoor equipment.
Stock Details
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2017-03-17 | Webuy | Geron investment in Series A - Webuy | 3 M CNY |
| 2016-08-28 | UnionCotton | Geron investment in Seed Round - UnionCotton | N/A |
| 2016-07-18 | Isoubu | Geron investment in Series A - Isoubu | 50 M CNY |
More informations about "Geron"
Our tireless pursuit - Geron
Powered by pioneering science, grounded in world-class expertise, and driven by purpose, Geron aims to change lives by changing the course of blood cancer. Nobel Prize-winning discoveries about an enzyme called telomerase and its …See details»
Geron Corporation - Wikipedia
Geron Corporation has sponsored human clinical trials of several potential anti-cancer products. • Imetelstat (GRN163L) is a drug that targets telomerase. In studies conducted at Johns Hopkins University, GRN163L was active against both CD138+ and CD138neg cancer stem cells and eliminated the colony forming potential of both by five weeks. Similarly, GRN163L inhibited the in vitro clonogenic growth of CD138neg Multiple Myeloma Cancer Stem Cells isolated from the bo…See details»
Geron Corporation - Investors & Media
Geron is a commercial-stage biopharmaceutical company with a first-in-class telomerase inhibitor that is approved in the United States for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) …See details»
Geron Corporation (GERN) - Yahoo Finance
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops …See details»
Geron Corporation (GERN) Stock Price, News, Quote & History
Find the latest Geron Corporation (GERN) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Our story continues to evolve - Geron
Geron.com. Geron Corporation – Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes. Accessed November 3, 2022. xvii Imetelstat Achieves Meaningful and Durable …See details»
Geron Corporation Reports Third Quarter 2024 Financial Results …
FOSTER CITY, Calif., November 07, 2024--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood …See details»
Geron Announces FDA Approval of RYTELO™ …
FOSTER CITY, Calif., June 07, 2024--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced ...See details»
Geron Corporation - Geron Announces New Data to be Presented …
Nov 5, 2024 FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course …See details»
Geron Corporation (GERN) Stock Price, Quote & News
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 …See details»
Geron Corporation - Geron Corporation Reports Fourth Quarter …
Mar 10, 2022 Top-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Expected in Early January 2023 Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical …See details»
Our leadership team - Geron
Our leadership. With a seasoned leadership team with world-class expertise spanning research, clinical development, regulatory, manufacturing and commercial experience in hematologic …See details»
Geron Corporation Announces Up to $375 Million in Funding with …
Nov 7, 2024 Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced up …See details»
Geron Corporation Announces Appointment of Joseph Eid, M.D. as ...
Nov 11, 2024 FOSTER CITY, Calif., November 11, 2024--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the …See details»
Geron Corporation (GERNW) Price & News - Google Finance
Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.See details»
Geron : Imetelstat Versus Best Available Therapy in Patients with ...
8 hours ago Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. …See details»
Geron Corporation (GERN) - Yahoo Finance
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors. FOSTER CITY, Calif., November 07, 2024--Geron Corporation (Nasdaq: …See details»
Advancing how blood cancers are treated | Geron
Scientific research has shown that telomerase activity is increased in malignant stem and progenitor cells in the bone marrow. Inhibiting telomerase activity aims to potentially reduce …See details»
The Manufacturers Life Insurance Company Has $3.16 Million …
10 hours ago Geron Corporation: FDA Approval Fuels Stock Price Surge; A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. …See details»
Geron Corporation Reports Second Quarter 2022 Financial Results
Aug 11, 2022 Top-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Continue to be Expected in Early January 2023 Current and Projected Financial Resources Expected to …See details»